Milestone Pharmaceuticals Inc. (NASDAQ:MIST – Get Rating) was the target of a large growth in short interest in April. As of April 15th, there was short interest totalling 1,280,000 shares, a growth of 44.6% from the March 31st total of 884,900 shares. Currently, 7.3% of the shares of the stock are short sold. Based on an average daily trading volume, of 110,300 shares, the short-interest ratio is currently 11.6 days.
Several institutional investors have recently modified their holdings of MIST. JPMorgan Chase & Co. purchased a new position in shares of Milestone Pharmaceuticals in the 4th quarter worth approximately $46,000. Acadian Asset Management LLC grew its position in shares of Milestone Pharmaceuticals by 63.0% in the 4th quarter. Acadian Asset Management LLC now owns 12,381 shares of the company’s stock worth $79,000 after buying an additional 4,785 shares during the last quarter. National Bank of Canada FI purchased a new stake in Milestone Pharmaceuticals during the 4th quarter worth approximately $96,000. Royal Bank of Canada grew its position in Milestone Pharmaceuticals by 13,063.3% during the 3rd quarter. Royal Bank of Canada now owns 26,195 shares of the company’s stock worth $149,000 after purchasing an additional 25,996 shares during the last quarter. Finally, Dimensional Fund Advisors LP grew its position in Milestone Pharmaceuticals by 15.5% during the 4th quarter. Dimensional Fund Advisors LP now owns 52,578 shares of the company’s stock worth $345,000 after purchasing an additional 7,061 shares during the last quarter. 66.89% of the stock is currently owned by hedge funds and other institutional investors.
A number of equities analysts have commented on MIST shares. Piper Sandler raised shares of Milestone Pharmaceuticals from a “neutral” rating to an “overweight” rating and lifted their price objective for the stock from $8.00 to $10.00 in a research note on Thursday, April 21st. HC Wainwright reiterated a “buy” rating on shares of Milestone Pharmaceuticals in a report on Tuesday, March 29th. Finally, Zacks Investment Research lowered shares of Milestone Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Wednesday, March 30th.
Milestone Pharmaceuticals (NASDAQ:MIST – Get Rating) last issued its quarterly earnings data on Thursday, March 24th. The company reported ($0.40) earnings per share (EPS) for the quarter. On average, research analysts predict that Milestone Pharmaceuticals will post -1.67 EPS for the current fiscal year.
Milestone Pharmaceuticals Company Profile (Get Rating)
Milestone Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines. The company is developing etripamil, a novel channel blocker, which is in Phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada; and Phase II clinical trial for the treatment of atrial fibrillation and rapid ventricular rate.
- Get a free copy of the StockNews.com research report on Milestone Pharmaceuticals (MIST)
- Why is Chevron Stock Falling After Strong Earnings?
- MarketBeat: Week in Review 4/25 – 4/29
- Apple’s Numbers Complete Trifecta
- Rogers Communication Stock Should Be Launching Higher
- O’Reilly Automotive Hits A Pothole
Receive News & Ratings for Milestone Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Milestone Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.